Patent details

Basic Information

Publication number:

EP3169709

PCT Application Number:

US2015040211

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP157397639

PCT Publication Number:

WO2016010924

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

CRYSTALLINE ANTIBODY FORMULATIONS

French Title of Invention:

FORMULATIONS D'ANTICORPS CRISTALLINES

German Title of Invention:

KRISTALLINE ANTIKÖRPERFORMULIERUNGEN

SPC Number:

Dates

Filing date:

13/07/2015

Grant date:

12/05/2021

EP Publication Date:

24/05/2017

PCT Publication Date:

21/01/2016

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

12/05/2021

EP B1 Publication Date:

12/05/2021

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

13/07/2021

Expiration date:

13/07/2035

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

05/05/2021

 

 

Name:

Amgen Inc.

Address:

One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States (US)

Inventor

1

Name:

TWINKLE, Christian R.

Address:

United States (US)

2

Name:

OSSLUND, Timothy David

Address:

United States (US)

3

Name:

CLOGSTON, Christi L.

Address:

United States (US)

Priority

Priority Number:

201462024399 P

Priority Date:

14/07/2014

Priority Country:

United States (US)

Classification

IPC classification:

C07K 16/40;

Publication

European Patent Bulletin

1

Issue number:

202119

Publication date:

12/05/2021

Description:

Grant (B1)

2

Issue number:

202124

Publication date:

16/06/2021

Description:

Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages